ArticleScientific reports2025
Stratification of G2 pancreatic neuroendocrine tumors using a Ten Percent Ki-67 index cut-off based on clinicopathological and molecular analyses.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Alternative lengthening of telomeres in small well-differentiated pancreatic neuroendocrine tumors: independent validation and cross-platform concordance.Virchows Archiv : an international journal of pathology · 2026Article
- A case of small pancreatic neuroendocrine tumor of less than 10 mm showing metastasis to multiple organs.Clinical journal of gastroenterology · 2026Article
- Real-world presentation and outcomes of gastroenteropancreatic neuroendocrine neoplasms in Italy: findings from the nationwide Itanet prospective database.The Lancet regional health. Europe · 2026Article
- Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system.Histopathology · 2026Review
- Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives.Journal of gastroenterology and hepatology · 2026Review
- The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center Analysis.Annals of surgical oncology · 2026Article
- Clinical Implications of Ki-67 Index, Grade and Hormonal Changes in Pancreatic Neuroendocrine Tumors: Insights Into Tumor Heterogeneity Based on Primary and Secondary Lesions.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.Virchows Archiv : an international journal of pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic neuroendocrine tumors (PanNETs) often have low malignancy, but some develop distant metastasis or recurrence. This study aimed to investigate the prognostic utility of a Ki-67 index 10% cut-off using clinicopathological and multiomics analyses. Eighty-seven resected PanNETs were classified as G1, G2-low, G2-high, and G3 according to the World Health Organization classification, incorporating a 10% Ki-67 threshold. These groups comprised 29 (33%), 33 (38%), 16 (18%), and 9 (10%) patients, respectively. Comprehensive analyses evaluated tumor characteristics and mutation profiles across the groups. Significant differences in tumor size, recurrence, and overall survival were observed between the G2-low and G2-high groups. Genomic profiling of 19 samples revealed that the G3 (4 patients) and G2-high (6 patients) groups showed greater tumor mutation burdens and more driver gene mutations than the G2-low (6 patients) and G1 (3 patients) groups. Gene expression profiling revealed distinct patterns between the G3/G2-high and G2-low/G1 groups, with the oncogene SERPINA1 significantly upregulated in the G3/G2-high group. The multiomics approach identified key genes, emphasizing the significance of the Ki-67 index 10% cut-off in predicting tumor behavior. The findings support using the Ki-67 index of 10% as a critical threshold for stratifying PanNETs and guiding prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.